EXEMESTANE, ANASTROZOLE, LETROZOLE, TAMOXIFEN
UC-BCG-2513
Phase 2 small_molecule active
Quick answer
EXEMESTANE, ANASTROZOLE, LETROZOLE, TAMOXIFEN for Postmenopausal patients with small (pT1a-b pN0) hormone receptor positive (HR⁺) and HER2 negative (HER2⁻) early breast cancer with a Luminal A phenotype and at low risk of recurrence. is a Phase 2 program (small_molecule) at Cancer Prevention Pharma (Ireland) Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Cancer Prevention Pharma (Ireland) Limited
- Indication
- Postmenopausal patients with small (pT1a-b pN0) hormone receptor positive (HR⁺) and HER2 negative (HER2⁻) early breast cancer with a Luminal A phenotype and at low risk of recurrence.
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active